HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection

Salim I. Khakoo(New York Academy of Medicine), Chloe L. Thio(New York Academy of Medicine), Maureen P. Martin(New York Academy of Medicine), Collin Brooks(New York Academy of Medicine), Xiaojiang Gao(New York Academy of Medicine), Jacquie Astemborski(New York Academy of Medicine), Jie Cheng(New York Academy of Medicine), James J. Goedert(New York Academy of Medicine), David Vlahov(New York Academy of Medicine), Margaret W. Hilgartner(New York Academy of Medicine), S.T. Cox(New York Academy of Medicine), Ann-Margeret Little(New York Academy of Medicine), Graeme Alexander(New York Academy of Medicine), Matthew Cramp(New York Academy of Medicine), Stephen J. O’Brien(New York Academy of Medicine), William Rosenberg(New York Academy of Medicine), David L. Thomas(New York Academy of Medicine), Mary Carrington(New York Academy of Medicine)
Science
August 5, 2004
10.1126/science.1097670
Cited by 1,181

Abstract

Natural killer (NK) cells provide a central defense against viral infection by using inhibitory and activation receptors for major histocompatibility complex class I molecules as a means of controlling their activity. We show that genes encoding the inhibitory NK cell receptor KIR2DL3 and its human leukocyte antigen C group 1 (HLA-C1) ligand directly influence resolution of hepatitis C virus (HCV) infection. This effect was observed in Caucasians and African Americans with expected low infectious doses of HCV but not in those with high-dose exposure, in whom the innate immune response is likely overwhelmed. The data strongly suggest that inhibitory NK cell interactions are important in determining antiviral immunity and that diminished inhibitory responses confer protection against HCV.

Related Papers

No related papers found

Powered by citation graph analysis